AIM
HTGM

Acrospire Investment Management’s HTG Molecular Diagnostics, Inc. Common Stock HTGM Stock Holding History

Acrospire Investment Management’s Portfolio HTGM Stock Details HTGM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-1
Closed -$1K – 2640
2017
Q1 		$1K Buy
+1
New +$481 ﹤0.01% 2160

Other funds holding HTGM

NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
GIM
Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return
PI
Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return
VKH
Virtu KCG Holdings New York $3.6B AUM 17.11% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Acrospire Investment Management's HTGM Position: Q2 2017 in Review

Acrospire Investment Management sold out of HTG Molecular Diagnostics, Inc. Common Stock (HTGM) in Q2 2017, closing a stake of 1 share — an estimated $1K sold.

Acrospire Investment Management first reported a position in HTGM in Q1 2017 and held it in 1 quarter. The position peaked at $1K in Q1 2017. 18 funds tracked by Wall St. Rank hold HTGM as of Q2 2017.

  • Acrospire Investment Management reported no remaining HTG Molecular Diagnostics, Inc. Common Stock position as of Q2 2017 after selling out during the quarter.
  • Acrospire Investment Management sold 1 HTG Molecular Diagnostics, Inc. Common Stock share in Q2 2017, an estimated $1K.
  • Acrospire Investment Management first reported a position in HTG Molecular Diagnostics, Inc. Common Stock in Q1 2017 and held it in 1 quarter.
  • Acrospire Investment Management's HTG Molecular Diagnostics, Inc. Common Stock position peaked at $1K in Q1 2017.
  • 18 funds tracked by Wall St. Rank held HTG Molecular Diagnostics, Inc. Common Stock as of Q2 2017.

Based on Acrospire Investment Management's 13F filing for Q2 2017, filed 11 Aug 2017.